Bausch Health Companies Inc. concluded fiscal 2025 with a notable turnaround to profitability, reflecting a 441% year-over-year net income increase despite a challenging Q4 earnings miss. The Salix segment emerged as a critical revenue growth engine, offsetting softness in other businesses while the company progresses its RED-C Phase 3 clinical trials. Its capital structure shows improving liquidity and active debt management, though negative equity underscores continued leverage risks. Key future performance drivers hinge on clinical milestones, regulatory approvals, and effective capital allocation to sustain momentum.